Switzerland· 68793001
Paxlovid, Filmtabletten
A nirmatrelvir und ritonavir product containing nirmatrelvirum, ritonavirum, registered in Switzerland by Pfizer AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Nirmatrelvir und ritonavir is registered in 11 of 19 countries.
Countries holding a registration under ATC J05AE30 (nirmatrelvir und ritonavir), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Nirmatrelvir und ritonavir · ATC J05AE30
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of nirmatrelvir und ritonavir costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- Switzerland: $851.25 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Nirmatrelvir und ritonavir · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$851.25
The record
At a glance
Swissmedic (Switzerland)- Active substance
- nirmatrelvirum, ritonavirum
- Manufacturer
- Pfizer AG
- Country
- Switzerland (CH)
- ATC code
- J05AE30
- ATC class
- Nirmatrelvir und Ritonavir
- Defined daily dose
- 0.6 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806879300175 Blist 6 StkCHF 1058.95
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for nirmatrelvir und ritonavir.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nirmatrelvir und ritonavir · interactions on record
1 record
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Nirmatrelvir und ritonavir in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPAXLOVIDPfizer Europe MA EEIG, Bruxelles
- NorwayPaxlovidPfizer Europe MA EEIG
- CanadaPAXLOVIDPFIZER CANADA ULC
- FrancePAXLOVID 150 mg + 100 mg, comprimé pelliculéPFIZER EUROPE MA EEIG (BELGIQUE)
- IcelandPaxlovidPfizer Europe MA EEIG*
- NetherlandsPaxlovid 150 mg filmomhulde tabletten (PF-12345678) en 100 mg filmomhulde tabletten (ritonavir)Pfizer Europe MA EEIG
- PolandPaxlovidPfizer Europe MA EEIG
- SwedenPaxlovid 150 mg + 100 mg Filmdragerad tablettPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Paxlovid
- Liechtenstein · Paxlovid
- Norway · Paxlovid
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ffc5b7da-080c-4c57-b633-0af20681c8e3 GET /v1/drugs/ffc5b7da-080c-4c57-b633-0af20681c8e3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "nirmatrelvirum 150 mg + ritonavirum 100 mg",
"valid_from": "2026-03-01",
"limitations": "[{\"description\":\"PAXLOVID wird als antivirale Monotherapie für die Behandlung einer bestätigten Covid-19 Infektion (Positiver Erregernachweis Antigen/PCR und vorhandener Covid-19-Symptome) in folgenden Fällen vergütet:<br>\\n • in einer Dosierung von 300 mg Nirmatrelvir (zwei Tabletten zu je 150 mg) und 100 mg Ritonavir (eine Tablette zu 100 mg) zur gleichzeitigen Einnahme alle 12 Stunden, über einen Zeitraum von 5 Tagen<br>\\n • zur Frühbehandlung (ausser bei immunsupprimierten Personen vorzugsweise innerhalb von 5 Tagen nach Symptombeginn) bei Erwachsenen, die keine Sauerstofftherapie oder Hospitalisierung aufgrund von COVID-19 benötigen und für welche gemäss der aktuell gültigen Kriterienliste der Schweizerischen Gesellschaft für Infektiologie (SSI) (https://www.sginf.ch/guidelines/guidelines-overview.html) ein erhöhtes Risiko für einen schweren COVID-19-Verlauf besteht.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21529.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-03-01\",\"validTo\":\"2029-02-28\"}]",
"galenic_form": "Filmtabl 4x150 mg/2x100 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2023-12-01",
"self_retention_pct": 10
}See everything about nirmatrelvir und ritonavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.